Krissanapong Manotham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Krissanapong Manotham has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Amornpun Sereemaspun
Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2 shared publicationsSupreecha Chattong
Molecular and Cellular Biology Unit, Department of Medicine, Lerdsin General Hospital, Bangkok, Thailand,
2 shared publications- Supreecha Chattong
Department of Medical Research and Technology Assessment, National Cancer Institute, Thailand, Bangkok, THA
2 shared publications A Sereemaspun
Department of Anatomy, Faculty of Medicine Chulalongkorn University Bangkok Thailand
1 shared publicationA Sethpakadee
Renal Unit, Department of Medicine Lerdsin General Hospital Bangkok Thailand
1 shared publicationAnant Setpakdee
Renal Unit, Department of Medicine, Lerdsin General Hospital, Bangkok 10500, Thailand
1 shared publication
Latest Publications
- 29 August 2018
- Published by Springer Nature
- Vol. 1867, 125-138
Genome Editing of MSCs as a Platform for Cell Therapy
The rapid growing of genome editing technology leads to an optimistic expectation for the treatment of many incurable diseases. The core of genome editing relies on DNA-repairing processes which occur independently in each cell, thus generating a mix of genetic variation cells. Here, we describe the protocol of using mesenchymal stem cells as a platform to generate high purity of ZFN-edited patients’ cell clones which may be useful in conjunction with therapeutic cell conversion and reprograming.
- 29 August 2018
- Published by Springer Nature
- Vol. 1867, 125-138
Genome Editing of MSCs as a Platform for Cell Therapy
The rapid growing of genome editing technology leads to an optimistic expectation for the treatment of many incurable diseases. The core of genome editing relies on DNA-repairing processes which occur independently in each cell, thus generating a mix of genetic variation cells. Here, we describe the protocol of using mesenchymal stem cells as a platform to generate high purity of ZFN-edited patients’ cell clones which may be useful in conjunction with therapeutic cell conversion and reprograming.
- Open Access
- 1 August 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 2361-2369
Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance
Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance Kamontip Chaikomon,1,2 Supreecha Chattong,1,3 Theerasak Chaiya,1 Danai Tiwawech,4 Yongsak Sritana-Anant,5 Amornpun Sereemaspun,6 Krissanapong Manotham1 1Molecular and Cellular Biology Unit, Department of Medicine, Lerdsin General Hospital, Bangkok, Thailand; 2Medical Sciences Program, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3EST Laboratory, SS Manufacturing, Nonthaburi, Thailand; 4Research Division, National Cancer Institute, Bangkok, Thailand; 5Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand; 6Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Background: Doxorubicin (DOX) is the most widely used chemotherapeutic agent that has multimodal cytotoxicity. The main cytotoxic actions of DOX occur in the nucleus. The emergence of drug-resistant cancer cells that have the ability to actively efflux DOX out of the nucleus, and the cytoplasm has led to the search for a more effective derivative of this drug. Materials and methods: We created a new derivative of DOX that was derived via simple conjugation of the 3' amino group of DOX to the dexamethasone molecule. Results: Despite having a lower cytotoxic activity in MCF-7 cells, the conjugated product, DexDOX, exerted its actions in a manner that was different to that of DOX. DexDOX rapidly induced MCF-7 cell apoptosis without entering the nucleus. Further analysis showed that DexDOX increased cytosolic oxidative stress and did not interfere with the cell cycle. In addition, the conjugated product retained its cytotoxicity in multidrug resistance-1-overexpressing MCF-7 cells that had an approximately 16-fold higher resistance to DOX. Conclusion: We have synthesized a new derivative of DOX, which has the ability to overcome multidrug resistance-1-induced resistance. This molecule may have potential as a future chemotherapeutic agent. Keywords: doxorubicin, dexamethasone, drug-resistant tumor, bioconjugation, multidrug resistance, reactive oxygen species
- 1 August 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 2361-2369
Open AccessDoxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance
Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance Kamontip Chaikomon,1,2 Supreecha Chattong,1,3 Theerasak Chaiya,1 Danai Tiwawech,4 Yongsak Sritana-Anant,5 Amornpun Sereemaspun,6 Krissanapong Manotham1 1Molecular and Cellular Biology Unit, Department of Medicine, Lerdsin General Hospital, Bangkok, Thailand; 2Medical Sciences Program, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3EST Laboratory, SS Manufacturing, Nonthaburi, Thailand; 4Research Division, National Cancer Institute, Bangkok, Thailand; 5Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand; 6Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Background: Doxorubicin (DOX) is the most widely used chemotherapeutic agent that has multimodal cytotoxicity. The main cytotoxic actions of DOX occur in the nucleus. The emergence of drug-resistant cancer cells that have the ability to actively efflux DOX out of the nucleus, and the cytoplasm has led to the search for a more effective derivative of this drug. Materials and methods: We created a new derivative of DOX that was derived via simple conjugation of the 3' amino group of DOX to the dexamethasone molecule. Results: Despite having a lower cytotoxic activity in MCF-7 cells, the conjugated product, DexDOX, exerted its actions in a manner that was different to that of DOX. DexDOX rapidly induced MCF-7 cell apoptosis without entering the nucleus. Further analysis showed that DexDOX increased cytosolic oxidative stress and did not interfere with the cell cycle. In addition, the conjugated product retained its cytotoxicity in multidrug resistance-1-overexpressing MCF-7 cells that had an approximately 16-fold higher resistance to DOX. Conclusion: We have synthesized a new derivative of DOX, which has the ability to overcome multidrug resistance-1-induced resistance. This molecule may have potential as a future chemotherapeutic agent. Keywords: doxorubicin, dexamethasone, drug-resistant tumor, bioconjugation, multidrug resistance, reactive oxygen species
- Open Access
- 26 March 2015
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 22 (1) , 1-8
Generation of CCR5-defective CD34 cells from ZFN-driven stop codon-integrated mesenchymal stem cell clones
Homozygous 32-bp deletion of the chemokine receptor 5 gene (CCR5) is associated with resistance to human immunodeficiency virus (HIV) infection, while heterozygosity delays HIV progression. Bone marrow transplantation (BMT) from a 32/32 donor has been shown to cure an HIV-infected patient. However, the rarity of this mutation and the safety risks associated with current BMT protocols are the major obstacles to this treatment. Zinc finger nuclease (ZFN) targeting is a powerful method for achieving genomic disruption at specific DNA sites of interest. Taking advantage of the self-renewal and plasticity properties of stem cells, in this study, we successfully generated isogenic and six-cell clones of bone marrow-derived mesenchymal stem cells that carry the stop codon of the CCR5 gene by using a ZFN-mediated homology-directed repair technique. These cells were expandable for more than 5 passages, and thus show potential to serve as an individual’s cell factory. When Oct4 was overexpressed, the mutated cells robustly converted to CD34+ progenitor cells. We here reported the novel approach on generation of patients own CD34 cells from high fidelity ZFN-mediated HDR MSC clones. We believe that our approach will be beneficial in future HIV treatment.
- 26 March 2015
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 22 (1) , 1-8
Open AccessGeneration of CCR5-defective CD34 cells from ZFN-driven stop codon-integrated mesenchymal stem cell clones
Homozygous 32-bp deletion of the chemokine receptor 5 gene (CCR5) is associated with resistance to human immunodeficiency virus (HIV) infection, while heterozygosity delays HIV progression. Bone marrow transplantation (BMT) from a 32/32 donor has been shown to cure an HIV-infected patient. However, the rarity of this mutation and the safety risks associated with current BMT protocols are the major obstacles to this treatment. Zinc finger nuclease (ZFN) targeting is a powerful method for achieving genomic disruption at specific DNA sites of interest. Taking advantage of the self-renewal and plasticity properties of stem cells, in this study, we successfully generated isogenic and six-cell clones of bone marrow-derived mesenchymal stem cells that carry the stop codon of the CCR5 gene by using a ZFN-mediated homology-directed repair technique. These cells were expandable for more than 5 passages, and thus show potential to serve as an individual’s cell factory. When Oct4 was overexpressed, the mutated cells robustly converted to CD34+ progenitor cells. We here reported the novel approach on generation of patients own CD34 cells from high fidelity ZFN-mediated HDR MSC clones. We believe that our approach will be beneficial in future HIV treatment.
- Open Access
- 1 June 2014
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 8 (3) , 333-343
Original article. Human dental pulp stem cells as a potential feeder layer for human embryonic stem cell culture
Background: Human embryonic stem (hES) cells are pluripotent, and can differentiate into three germ layers. Traditionally, cultures of hES cells are maintained in a system containing mouse embryonic fibroblasts as a feeder layer for support of undifferentiated growth. However, contamination by animal cells limits the use of hES cells. Objective: We evaluated the use of human dental pulp stem cells (hDPSCs) as a feeder layer for hES cell culture. It should be possible to obtain a new source of human mesenchymal stem cells for feeder cells to maintain undifferentiated growth of hES cells. Methods: hDPSCs from removed impacted wisdom teeth (third molars) were extracted, cultured, and characterized for mesenchymal stem cell properties. Furthermore, hDPSCs were used as a feeder layer for culturing Chula2 and Chula5 hES cell lines. Finally, hES cell lines grown on hDPSCs feeders were examined embryonic stem cell properties. Results: We found that hDPSCs, which have mesenchymal properties, can support undifferentiated growth of hES cell lines. After prolonged culture (passage 17), these hES cell lines still maintain ES cell properties including typical morphology seen in hES cells, the expression of pluripotency markers (Oct4, Sox2, Nanog, Rex1, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81), embryoid body formation and retention of a normal karyotype. Conclusion: hDPSCs, derived from the pulp tissue of impacted third molars, are a potential source of human feeder cells for the culture of undifferentiated hES cells.
- 1 June 2014
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 8 (3) , 333-343
Open AccessOriginal article. Human dental pulp stem cells as a potential feeder layer for human embryonic stem cell culture
Background: Human embryonic stem (hES) cells are pluripotent, and can differentiate into three germ layers. Traditionally, cultures of hES cells are maintained in a system containing mouse embryonic fibroblasts as a feeder layer for support of undifferentiated growth. However, contamination by animal cells limits the use of hES cells. Objective: We evaluated the use of human dental pulp stem cells (hDPSCs) as a feeder layer for hES cell culture. It should be possible to obtain a new source of human mesenchymal stem cells for feeder cells to maintain undifferentiated growth of hES cells. Methods: hDPSCs from removed impacted wisdom teeth (third molars) were extracted, cultured, and characterized for mesenchymal stem cell properties. Furthermore, hDPSCs were used as a feeder layer for culturing Chula2 and Chula5 hES cell lines. Finally, hES cell lines grown on hDPSCs feeders were examined embryonic stem cell properties. Results: We found that hDPSCs, which have mesenchymal properties, can support undifferentiated growth of hES cell lines. After prolonged culture (passage 17), these hES cell lines still maintain ES cell properties including typical morphology seen in hES cells, the expression of pluripotency markers (Oct4, Sox2, Nanog, Rex1, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81), embryoid body formation and retention of a normal karyotype. Conclusion: hDPSCs, derived from the pulp tissue of impacted third molars, are a potential source of human feeder cells for the culture of undifferentiated hES cells.
- 18 December 2012
- Published by Wiley in British Journal of Pharmacology
- Vol. 168 (1) , 189-199
Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production
Background and Purpose: Recombinant human erythropoietin ( rHuEPO ) is currently the mainstay of renal anaemia treatment. Recently, rHuEPO has been shown to provide pleiotrophic tissue protection in various pathological conditions. However, the benefits of rHuEPO beyond anaemia treatment are limited because it increases red blood cell mass. Carbamylated erythropoietin (CEPO) is the first rHuEPO derivative that lacks erythropoietic activity but retains tissue protection properties. Since carbamylation targets lysine residues on rHuEPo , we hypothesized that targeted lysine modifications of rHuEPO may result in a novel non‐erythropoietic erythropoietin.Experimental Approach: rHuEPO was subjected to various targeted lysine modifications. In vitro cytoprotection and apoptosis were evaluated using P19 and HEK293 cells. In vivo erythropoiesis was performed by administering the derivatives to animals for 2 weeks. Renoprotection was tested on an ischaemia/reperfusion (I/R) model.Key Results: We synthesized a novel derivative, a glutaraldehyde erythropoietin (GEPO). This construct abolished in vivo erythropoiesis. Biochemical characterization showed that GEPO was more electrostatically negative than rHuEPO . Immunoprecipitation experiments revealed that GEPO bound to the IL3RB/EPOR heterotrimeric receptor and ameliorated cellular apoptosis via the activation of Bcl‐2. Notably, Bcl‐2 activation was suppressed by the JAK2 inhibitor, tyrphostin AG490. In vivo experiments showed that GEPO also ameliorated kidney damage due to I/R injury both functionally and histologically.Conclusions and Implications: Herein, we describe a novel lysine‐modified rHuEPO , glutaradehyde‐EPO (GEPO), obtained from a simple reaction. This derivative has no erythropoietic properties but retains cell‐protective characteristics both in vitro and in vivo, with promise for future use as an adjunctive treatment of kidney disease.
- 18 December 2012
- Published by Wiley in British Journal of Pharmacology
- Vol. 168 (1) , 189-199
Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production
Background and Purpose: Recombinant human erythropoietin ( rHuEPO ) is currently the mainstay of renal anaemia treatment. Recently, rHuEPO has been shown to provide pleiotrophic tissue protection in various pathological conditions. However, the benefits of rHuEPO beyond anaemia treatment are limited because it increases red blood cell mass. Carbamylated erythropoietin (CEPO) is the first rHuEPO derivative that lacks erythropoietic activity but retains tissue protection properties. Since carbamylation targets lysine residues on rHuEPo , we hypothesized that targeted lysine modifications of rHuEPO may result in a novel non‐erythropoietic erythropoietin.Experimental Approach: rHuEPO was subjected to various targeted lysine modifications. In vitro cytoprotection and apoptosis were evaluated using P19 and HEK293 cells. In vivo erythropoiesis was performed by administering the derivatives to animals for 2 weeks. Renoprotection was tested on an ischaemia/reperfusion (I/R) model.Key Results: We synthesized a novel derivative, a glutaraldehyde erythropoietin (GEPO). This construct abolished in vivo erythropoiesis. Biochemical characterization showed that GEPO was more electrostatically negative than rHuEPO . Immunoprecipitation experiments revealed that GEPO bound to the IL3RB/EPOR heterotrimeric receptor and ameliorated cellular apoptosis via the activation of Bcl‐2. Notably, Bcl‐2 activation was suppressed by the JAK2 inhibitor, tyrphostin AG490. In vivo experiments showed that GEPO also ameliorated kidney damage due to I/R injury both functionally and histologically.Conclusions and Implications: Herein, we describe a novel lysine‐modified rHuEPO , glutaradehyde‐EPO (GEPO), obtained from a simple reaction. This derivative has no erythropoietic properties but retains cell‐protective characteristics both in vitro and in vivo, with promise for future use as an adjunctive treatment of kidney disease.
- 12 October 2011
- Published by Wiley in Internal Medicine Journal
- Vol. 42 (4) , e33-e37
Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre‐/post‐study
Chronic intrarenal hypoxia has been regarded as a pathogenic factor of progressive renal damage. However, the lack of available human data has impeded the progress in this field. In this work, blood oxygen level‐dependent magnetic resonance imaging was used to determine intrarenal oxygen status pre‐ and post‐angiotensin receptor blockade (olmesartan) treatment in normal subjects, diabetic chronic kidney disease (CKD) patients and non‐diabetic CKD patients. The mean R2*, which represents intrarenal oxygenation, was significantly lower in the control group than in the CKD group (12.42 ± 0.53 /s vs 18.89 ± 3.15 /s, P < 0.01), indicating the presence of intrarenal hypoxia in the CKD patients. The olmesartan treatment induced a 16.2 ± 7.7% decrement of the mean R2* in CKD patients, suggesting that this drug had an intrarenal hypoxia ameliorating effect.
- 12 October 2011
- Published by Wiley in Internal Medicine Journal
- Vol. 42 (4) , e33-e37
Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre‐/post‐study
Chronic intrarenal hypoxia has been regarded as a pathogenic factor of progressive renal damage. However, the lack of available human data has impeded the progress in this field. In this work, blood oxygen level‐dependent magnetic resonance imaging was used to determine intrarenal oxygen status pre‐ and post‐angiotensin receptor blockade (olmesartan) treatment in normal subjects, diabetic chronic kidney disease (CKD) patients and non‐diabetic CKD patients. The mean R2*, which represents intrarenal oxygenation, was significantly lower in the control group than in the CKD group (12.42 ± 0.53 /s vs 18.89 ± 3.15 /s, P < 0.01), indicating the presence of intrarenal hypoxia in the CKD patients. The olmesartan treatment induced a 16.2 ± 7.7% decrement of the mean R2* in CKD patients, suggesting that this drug had an intrarenal hypoxia ameliorating effect.